Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1982 1
1983 2
1985 1
1986 3
1987 6
1988 3
1989 4
1990 4
1991 3
1992 9
1993 6
1994 3
1995 9
1996 6
1997 6
1998 7
1999 4
2000 4
2001 4
2002 1
2003 2
2004 3
2005 5
2006 3
2007 4
2008 3
2009 5
2010 5
2011 4
2012 3
2013 7
2014 8
2015 4
2016 2
2017 3
2018 4
2019 3
2020 3
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

150 results
Results by year
Filters applied: . Clear all
Page 1
PIM kinase (and Akt) biology and signaling in tumors.
Warfel NA, Kraft AS. Warfel NA, et al. Among authors: kraft as. Pharmacol Ther. 2015 Jul;151:41-9. doi: 10.1016/j.pharmthera.2015.03.001. Epub 2015 Mar 5. Pharmacol Ther. 2015. PMID: 25749412 Free PMC article. Review.
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.
Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, Armeson KE, Schuetze SM, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Kraft AS. Somaiah N, et al. Among authors: kraft as. Cancer. 2021 Mar 15;127(6):894-904. doi: 10.1002/cncr.33216. Epub 2020 Nov 24. Cancer. 2021. PMID: 33231866
Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase.
Song JH, Singh N, Luevano LA, Padi SKR, Okumura K, Olive V, Black SM, Warfel NA, Goodrich DW, Kraft AS. Song JH, et al. Among authors: kraft as. Mol Cancer Ther. 2018 Dec;17(12):2710-2721. doi: 10.1158/1535-7163.MCT-18-0374. Epub 2018 Sep 6. Mol Cancer Ther. 2018. PMID: 30190422 Free PMC article.
150 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page